Clinical Trial Update: An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH) [Phase 4]

View source ↗

Summary

Phase 4 open-label study assessing safety and efficacy of ambrisentan in exercise-induced pulmonary arterial hypertension completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Exercise-induced Pulmonary Arterial Hypertension
• Pulmonary Arterial Hypertension

Drugs mentioned

• Ambrisentan (Ambrisentan)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Exercise-induced Pulmonary Arterial Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2017-05-22